The Journal of Experimental Medicine
StemCell Technologies
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

Published online 10 March 2003 doi:10.1084/jem.20021493
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow PPT slides of all figures
Right arrow Alert me when this article is cited
Right arrow Citation Map
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new content in the JEM
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Johnson, L. L.
Right arrow Articles by Smiley, S. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Johnson, L. L.
Right arrow Articles by Smiley, S. T.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
© Rockefeller University Press, 0022-1007/2003/3/801 $5.00
The Journal of Experimental Medicine, Volume 197, Number 6, 801-806


Brief Definitive Report

Fibrin-mediated Protection Against Infection-stimulated Immunopathology

Lawrence L. Johnson1, Kiera N. Berggren1, Frank M. Szaba1, Wangxue Chen2 and Stephen T. Smiley1

1 Trudeau Institute, Saranac Lake, NY 12983
2 Institute for Biological Sciences, National Research Council of Canada, Ottawa, ON K1AORG, Canada

Address correspondence to Stephen T. Smiley, Trudeau Institute, 100 Algonquin Ave., Saranac Lake, NY 12983. Phone: 518-891-3080; Fax: 518-891-5126; E-mail: ssmiley{at}trudeauinstitute.org

Fibrin, a product of the blood coagulation cascade, accompanies many type 1 immune responses, including delayed-type hypersensitivity, autoimmunity, and graft rejection. In those settings, fibrin is thought to exacerbate inflammation and disease. Here, we evaluate roles for coagulation during infection with Toxoplasma gondii, a pathogen whose control requires robust type 1 immunity. We establish that fibrin prevents infection-stimulated blood loss, thereby performing a protective function that is essential for survival. Remarkably, fibrin does not simply protect against vascular damage caused directly by the infectious agent, but rather, protects against hemorrhage evoked by interferon-{gamma}, a critical mediator of type 1 immunity. This finding, to our knowledge, is the first to document a beneficial role for coagulation during type 1 immunity, and suggests that fibrin deposition protects host tissue from collateral damage caused by the immune system as it combats infection.

Key Words: cellular immunity • interferon type II • toxoplasma • blood coagulation • hemorrhage


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:



  Home | Help | Feedback | Subscriptions | Archive | Search
TABLE OF CONTENTS